A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

NCT ID: NCT01279616

Last Updated: 2019-04-03

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-09-30
• Study Completion Date: 2015-01-31

Brief Summary

Majority of patients who are eligible for allogeneic HSCT for cure of severe sickle cell disease lack a matched family donor. This study aims for cure of sickle cell disease by performing unrelated donor (outside family) allogeneic HSCT. Donors or unrelated cord blood units will be selected from the NMDP database. It is designed to estimate the safety of a novel reduced toxicity, yet an immunosuppressive and myeloablative preparative regimen. This is meant for patients <21 years old who have severe complications from sickle cell and do not have matched sibling donors in the family to undergo stem cell transplant. Patients will undergo transplant using unrelated donor stem cells after receiving the protocol therapy. They will be followed for 1 year to monitor for engraftment of donor cells and complications like graft versus host disease (GVHD), infections and death.

Detailed Description

The primary goal of this pilot study is to determine the safety and feasibility of the preparative regimen for HSCT using a novel reduced toxicity regimen for stem cell transplant with unrelated donors. Analysis will be geared to confirm if the study regimen, followed by an appropriately HLA-matched unrelated donor (MUD)or unrelated cord blood HSCT, can lead to durable donor engraftment with reasonable toxicity, inhibiting sickle erythropoiesis and limiting disease related organ toxicity in patients who are at high risk for morbidity and mortality associated with sickle cell disease (SCD).

Conditions

Sickle Cell Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Hematopoietic Stem Cell Transplant

Stem cell infusion on Day 0.

Group Type: EXPERIMENTAL

Fludarabine monophosphate

Intervention Type: DRUG

180 mg/m2 over 6 days.

Rituximab

Intervention Type: DRUG

375 mg/m2 on day -13 and day -3

Busulfan

Intervention Type: DRUG

AUC 1000-1200 microM.mt

ATG

Intervention Type: DRUG

2.5 mg/kg for 3 days

Cyclophosphamide

Intervention Type: DRUG

50 mg/kg on day +3

Mycophenolate mofetil

Intervention Type: DRUG

15 mg/kg q 8 hours

Tacrolimus

Intervention Type: DRUG

0.03 mg/kg /d

Interventions

Fludarabine monophosphate

180 mg/m2 over 6 days.

Intervention Type: DRUG

Rituximab

375 mg/m2 on day -13 and day -3

Intervention Type: DRUG

Busulfan

AUC 1000-1200 microM.mt

Intervention Type: DRUG

ATG

2.5 mg/kg for 3 days

Intervention Type: DRUG

Cyclophosphamide

50 mg/kg on day +3

Intervention Type: DRUG

Mycophenolate mofetil

15 mg/kg q 8 hours

Intervention Type: DRUG

Tacrolimus

0.03 mg/kg /d

Intervention Type: DRUG

Other Intervention Names

Rituxan; busulfex; Thymoglobulin; Cytoxan; MMF, Cell-cept.; FK-506

Eligibility Criteria

Inclusion Criteria

Patients must have sickle cell disease (genotype Hb SS or Sß° thalassemia), AND must have 1 or more of the following clinical complications related to Sickle cell disease:

1. A clinically significant neurologic event (stroke) or any neurologic defect lasting >24 hours, that is accompanied by an infarct on cerebral MRI.

2. Minimum of two episodes of acute chest syndrome (defined as new pulmonary alveolar consolidation involving at least 1 complete lung segment associated with acute symptoms including fever, chest pain, tachypnea, wheezing or cough) despite adequate supportive care measures (example: asthma therapy, hydroxyurea).

3. History of severe pain episodes defined as 3 or more severe pain events per year in the 2 years prior to enrollment despite adequate supportive care measures and hydroxyurea trial (i.e. Hydroxyurea non-responders). Pain may occur in typical sites associated with vaso-occlusive painful events and cannot be explained by causes other than vaso-occlusion mediated by sickle cell disease.

4. Recurrent priapism.

5. Osteo-necrosis of multiple joints

6. Evidence of Pulmonary Hypertension as evidenced by Tricuspid Regurgitation jet velocity (TRV) > 2.5 m/s on Echocardiogram.

7. Red cell allo-immunization (≥ 2 antibodies) during long term transfusion therapy.

Exclusion Criteria

1. Invasive bacterial, viral or fungal infections within 1 month prior to starting conditioning therapy.

2. Female patients who are Pregnant (Beta HCG +) or breastfeeding.

3. HIV positive patients.

4. Patients with HLA-matched related family donors are not eligible for this study.

5. Prior myeloablative allogeneic HCT.

6. Patients on chronic transfusion therapy for ≥ 1 year with evidence of cirrhosis of liver on biopsy

7. Any significant concurrent disease, illness, severe cognitive delay or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.

• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nationwide Children's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sandeep Soni, MD

Role: STUDY_CHAIR

Nationwide Children's Hospital

Locations

Nationwide Children's Hospital

Columbus, Ohio, United States

Countries

United States

Other Identifiers

09-00383

Identifier Type: -

Identifier Source: org_study_id